Recognized by the legal directories as one of the leading law firms for Life Sciences in Israel, our corporate and commercial Bio-tech and Medical Device Group advises on every commercial aspect relating to the business and innovation cycle of a life science company. We act for clients across the entire industry – including both innovative and generic manufacturers of pharmaceutical products, medical and healthcare start-ups (including health improvement, life quality and wellness), medical device developers, venture capital funds, academic and research institutions, healthcare providers and other entities that provide to the sector finance, services, technology and collaborative research and development.

We advise founders and early stage companies on corporate structuring, licensing, founder agreements, incentive schemes, clinical trials, registrations, tax, obtaining and registering clear chain of IP title and, most importantly, preparing and successfully executing fund raising whether from angels or venture capital funds. For clients at a more developed stage, we advise on commercialization of IP, the entering into of existing and potential markets, collaboration, research and development, technology transfers, routes of supply, further fund raising (debt financings), management and exits (whether by way of M&A or an IPO).

S.Horowitz & Co. is one of the few firms in Israel that has an in depth knowledge of the industry with the various skill sets and expertise to provide on-going advice on all legal and regulatory aspects concerning the development, testing, financing and commercialization of pharmaceuticals and medical devices. Our understanding of the business and our expertise in the field makes us unique in Israel for being able to provide a multidisciplinary approach to the life science sector that can deliver more than just the core corporate capabilities.



  • Representing Yeda Research and Development Limited (the commercialization arm of the Weizmann Institute of Science, one of Israel’s largest and most prestigious research institutions) on a large number of technology transfer agreements in the biotech field, including research and license agreements, evaluation and option agreements and consulting agreements.
  • Representing Dexcel, the second largest generic drug manufacturer in Israel, which operates also in the US and Europe, on various regulatory and commercial matters regarding a broad range of cases in the field of healthcare and particularly in the field of pharmaceuticals and medical devices.
  • Advising Cardinal Health, a global healthcare company listed on the NYSE, on the Israeli law aspects of its $6.1 billion acquisition of Medtronic’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses.
  • Representing Hadassah Medical Organization in various commercial and litigation, including regulatory, matters.
  • Representing Chengdu Kanghong Pharmaceutical Group (listed on the Shenzhen stock exchange), in their staged acquisition of I-Optima – an Israeli company which manufactures and markets a surgical device for treatment of glaucoma.
  • Representing Becton Dickinson and Co – a medical technology company traded on NYSE in its acquisition of the assets of Lapidot Group, an Israeli company specializing in marketing and distribution of branded pharmaceuticals and medical products.
  • Representing institutional investors in a Series D Preferred investment in EarlySense Ltd., a medical-device company which developed a patient monitoring system.
  • Representing Spectranetics Corporation, a world leading manufacturer and supplier of medical equipment for use in minimally invasive interventional procedures, in its acquisition of Upstream Technologies Ltd., an Israeli company which specialises in developing new technologies for the manufacturing of medical equipment.
  • Representing Radius Ventures, a US investment fund, on its investments in bio-tech companies in Israel (one such transaction includes acting for Radius on the sale of Medingo to Hoffman La Roche for $160 million plus $40 million additional milestone payments).
  • Representing AstraZeneca plc and Minrav Holdings Ltd. on their participation in a tender to establish a life science incubator as part of the Office of the Chief Scientist’s incubator program.
  • Representing Medial Early Sign Ltd., a medical device and analytics start up, on various financing rounds in a total amount of $50 million, including investment by Hong Kong-based Horizons Ventures in an amount of $30 million, as well as on-going commercial, corporate and regulatory matters, including license and research agreements with leading research institutions, health organizations and insurance companies.
  • Representing a group of angel investors on a large number of seed equity and debt investments in a variety of new biotech companies, with an emphasis on companies engaging in medical developments with meaningful contributions to society (such as the development of wearable medical equipment for the identification of congestive heart failure, an innovative scanner for use during oncological surgeries, a catheter for patients with heart diseases and a physiotherapy tool and communication software for children with special needs).
  • Represented Neusoft Group Ltd. (China’s largest IT and software company) on its acquisition of a controlling interest in Aerotel Medical Systems Ltd., a leading medical device company which designs and manufactures digital patient monitoring systems.
  • Represented Zimmer Biomet, a publicly traded medical device company and a leading manufacturer of medical devices, on the acquisition of the distribution business of its local distributor, Bepex Limited, and of the assets associated with such business, including the IP rights.
  • Represented Zimmer Surgical, Inc. and Zimmer Dental Ltd. in the acquisition of the assets of Medical Compression System (D.B.N.) Ltd., an Israeli public company which develops products and technologies for use in treating and preventing deep vein thrombosis, pulmonary embolisms and similar conditions.
  • Representing Galmed Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development and commercialization of a therapy for treating liver diseases, in a series of license agreements with Far Eastern and South American licensees, and in an inward investment.
  • Representing Mediseen eHealth, the developer of DDI+, a web-based, patient-centric software platform for handling patients’ drug-related problems (DRPs) in the licensing out of its platform to a number of medical centres in Germany, and in the licensing in of complementary software for integration into its platform from Treat Solutions, a Danish company.
  • Providing Teva Pharmaceuticals, one of the world’s largest generic drug companies, with ongoing consulting and representation on a wide scope of aspects regarding the registration, manufacture, import and marketing of diverse pharmaceutical products, the law regarding conducting clinical trials in Israel, genetic tests, infant nutrition and more. Additionally, we represented Teva Pharmaceuticals in a number of investments in drug development companies.
  • Advising and representing MAoI (The Chemical, Pharmaceutical and Environmental Society of the Manufacturers’ Association of Israel) in a wide range of matters, including, life science matters, legislation and litigation, as well as in legal proceedings before the courts and the Patent Office in diverse matters relating to issues that have a general bearing on, and are important to, the entire pharmaceutical industry.
  • Representing Maccabi Healthcare Services in a long series of legal proceedings regarding the relationship between Maccabi and its members, as well as the relationship between Maccabi and the State of Israel, including: various class actions and derivative actions, privacy and regulatory matters.